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Copy number variants (CNVs) are chromosomal rearrangements
involving large segments of DNA (from 1000 and up to several
million base pairs in length) that can be deleted, duplicated,
inverted or translocated. A number of pathogenic CNVs are
known to cause clinically recognisable syndromes, such as
Williams–Beuren syndrome (WBS), Angelman/Prader–Willi
syndrome (AS/PWS) and velocardiofacial syndrome (VCFS).1
Some CNVs are associated with a highly variable phenotype,
which often includes both developmental and neuropsychiatric
disorders.1 For example, 22q11.2 deletions, the first CNV to be
associated with schizophrenia,2 also causes VCFS, which is
characterised by intellectual disability and a number of medical
problems such as palatal and skeletal anomalies and cardiac
defects.3,4 Several large and rare CNVs have now been implicated
in the aetiology of schizophrenia,5–13 reviewed by Malhotra &
Sebat.14 They have been shown to substantially increase risk for
the development of the disorder, from twofold to over 60-fold.14
Most of them have been shown to also increase risk for other
disorders, such as autism spectrum disorders, intellectual deficit,
developmental delay and epilepsy.1,14,15
As some of the CNVs are very rare (found in less than 1 in
1000 patients), notwithstanding the relatively large data-sets
examined so far (ranging between ~5000 and 14 000 people with
schizophrenia), it is not clear that all those that have been
implicated are true risk factors for the disorder. Thus, for nine
of the loci that have received the strongest support in the
literature,14 fewer than 15 observations have been made in people
with schizophrenia. These nine loci are: duplications at 1q21.1,10
the WBS region,16 the AS/PWS region,6 at VIPR2,10,17 at
16p13.117 and deletions at 3q29,10,12 distal 16p11.2,18 17q1219
and 17p12.20 The evidence for six loci is based only on single,
albeit very large, studies: deletions at 17q12,19 distal 16p11.218
and 17p1220 and duplications at 1q21.1,10 AS/PWS region6 and
at 16p13.11.7 Moreover, the role of two loci, deletions at
15q11.2 and duplications at 16p13.11, has recently been
challenged by a study that indicated that the rates among controls
might be higher than originally reported,5 and no excess in
individuals with schizophrenia was seen for these two CNVs in
one of the largest studies.10 Finally, each previous report focused
on the identification of one, or only a small number of CNV loci,
and several reports used partially overlapping data-sets.
Consequently, the rate of all previously reported risk CNVs has
not yet been evaluated in a single independent data-set that is
not biased by the inclusion of the original discovery sample. We
set out to evaluate these specific CNVs in a sample of 6882 people
with schizophrenia that passed quality control. This represents
the largest single CNV data-set yet reported in schizophrenia,
and nearly doubles the sample size of patients from the total
world literature for many loci. For control individuals, we used
publicly available data from 6316 samples genotyped on arrays
with a resolution similar to the case group. These data-sets are
completely independent from samples used in previous studies
or reviews that established the rates of these CNVs in
schizophrenia.
Method
Samples
Case group
We collected data on patients with schizophrenia (case group) in
two waves, which we call (a) CLOZUK and (b) CardiffCOGS
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Background
A number of copy number variants (CNVs) have been
suggested as susceptibility factors for schizophrenia.
For some of these the data remain equivocal, and the
frequency in individuals with schizophrenia is uncertain.
Aims
To determine the contribution of CNVs at 15 schizophrenia-
associated loci (a) using a large new data-set of patients
with schizophrenia (n=6882) and controls (n=6316),
and (b) combining our results with those from previous
studies.
Method
We used Illumina microarrays to analyse our data. Analyses
were restricted to 520 766 probes common to all arrays used
in the different data-sets.
Results
We found higher rates in participants with schizophrenia
than in controls for 13 of the 15 previously implicated CNVs.
Six were nominally significantly associated (P50.05) in this
new data-set: deletions at 1q21.1, NRXN1, 15q11.2 and
22q11.2 and duplications at 16p11.2 and the Angelman/
Prader–Willi Syndrome (AS/PWS) region. All eight AS/PWS
duplications in patients were of maternal origin. When
combined with published data, 11 of the 15 loci showed
highly significant evidence for association with schizophrenia
(P54.161074).
Conclusions
We strengthen the support for the majority of the previously
implicated CNVs in schizophrenia. About 2.5% of patients
with schizophrenia and 0.9% of controls carry a large,
detectable CNV at one of these loci. Routine CNV screening
may be clinically appropriate given the high rate of known
deleterious mutations in the disorder and the comorbidity
associated with these heritable mutations.
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(Cardiff Cognition in Schizophrenia). The CLOZUK sample
(n= 6558) consists of individuals taking the antipsychotic
clozapine. In the UK, clozapine is reserved for patients with
treatment-resistant schizophrenia, who provide regular blood
samples to allow detection of adverse drug effects. Through
collaboration with Novartis, the manufacturer of a proprietary
form of clozapine, we acquired anonymised blood samples from
people on clozapine. Participants (71% male) were aged 18–90,
with a recorded diagnosis of treatment-resistant schizophrenia
according to the clozapine registration forms completed by their
psychiatrists. The use of these anonymised samples for genetic
association studies was approved by the local ethics committee.
The CLOZUK sample has been described elsewhere.21 The
CardiffCOGS (n= 571) is a sample of patients with clinically
diagnosed schizophrenia recruited from community, in-patient
and voluntary sector mental health services in the UK. Interview
with the Schedules for Clinical Assessment in Neuropsychiatry
(SCAN) instrument22 and case-note review was used to arrive at
a best-estimate lifetime diagnosis according to DSM-IV criteria.23
Control group
As controls we used publicly available data downloaded from
dbGAP (www.ncbi.nlm.nih.gov/gap). To avoid CNV detection
biases between arrays with different probe densities and platforms,
we chose data-sets genotyped with Illumina arrays that had a high
overlap with the probes used to genotype the case group. The
following data-sets were used: 1491 participants from the USA
that took part in a study on smoking cessation, 3102 participants
from the USA who took part in a study on melanoma and 1869
participants from Germany who took part in a study of refractive
error (KORA study). Participants in the ‘smoking’ and
‘melanoma’ data-sets are cases or controls from these studies,
whereas the KORA data-set is a population-based study where
participants had refractive error measurements. The ethnicities
of participants were derived from principal components analysis
(PCA). A total of 91.4% of samples that passed quality control
were from individuals of European ancestry. Full details on these
data-sets are presented in the online supplement (section 1).
Genotyping and quality control filtering
Raw intensity files from each data-set were independently
processed to account for potential batch effects. PennCNV24 was
used for CNV detection. To avoid cross-platform biases, we
restricted CNV calling to the 520 766 probes present on all arrays
used. Samples were excluded if any one of the following standard
quality control statistics constituted an outlier within their source
data-set: log R ratio (LRR) standard deviation, B-allele frequency
(BAF) drift, wave factor (WF) and total number of CNVs (online
supplement, section 2). Out of 13 591 samples with array data, 393
were excluded due to poor quality control or for being duplicates
of the same individual after testing for identity-by-descent. The
8.6% non-European participants were retained in the analysis,
to ensure that our data were comparable with those in recent
reviews of CNV loci in schizophrenia.14 The numbers and
ethnicities of these participants are listed in online Table DS2.
The final numbers after exclusions for quality control and
duplicates was 6882 in the case group and 6316 in the control
group. The quality control process for individual CNVs is detailed
in the online supplement (section 2). Briefly, CNVs were included
if they were410 kb in size and had a frequency 51%, (applying
filters with PLINK version 1.07).25 All CNVs were subsequently
required to pass a median z-score outlier method of validation26
that helps to remove false-positive CNVs, and to identify any
missed CNVs.
Statistical analysis
For the analysis of CNV loci we used Fisher’s exact test (1-tailed as
we were testing prior hypotheses). We performed a meta-analysis
by adding our new data to those in the literature, applying a
2-tailed Fisher’s exact test to the combined data. As these CNVs
have been shown to be subjected to strong negative selection
pressure, their frequencies in the population essentially reflect
the mutation rate and selection pressure operating against
them.1,27 They are therefore less likely to be subjected to
population stratification caused by genetic drift, in the way
common variants are (although there are some examples of ethnic
differences in the mutation rates). Therefore, in the interests of
clarity, we do not stratify the sample by ethnicity but provide
the full breakdown of the data in the different ethnic groups in
online Table DS3. The results do not change appreciably if they
are restricted to only the European populations that comprise
91.4% of the sample.
There is no accepted convention as to what constitutes
genome-wide significance for a CNV locus. Girirajan and
colleagues1 reported 72 recurrent CNVs that can cause a neuro-
developmental disorder, although in total, 120 genomic regions
are potentially prone to recurrent CNVs because they are flanked
by segments of high homology, called segmental duplications.28
This suggests that a Bonferroni correction for multiple testing of
recurrent CNVs (those flanked by segmental duplications) might
require a P-value of 54.161074 to be accepted as a significant
association for this type of CNV (P=0.05/120). Regarding
associations with individual genes, a conservative Bonferroni
correction would require correcting for the testing of ~20 000
genes, or P52.561076 (P=0.05/20 000).
Choice of CNVs for analysis
The list of previously implicated CNVs was taken from the largest
meta-analysis to date.14 To this list we added three loci: exon-
disrupting deletions at the NRXN1 gene, as there is consensus that
they increase risk for developing schizophrenia;9,10,13 deletions at
distal 16p11.2, the evidence for which was published after the
above review;18 and duplications at the WBS region, a locus that
just failed to reach significance in that review, but received support
in a subsequent study.16 For duplications at the AS/PWS region,
we tested their parental origin using a DNA methylation-sensitive
high-resolution melting curve analysis,29 as previous research
suggested that the maternal ones are specifically implicated6
(online supplement, section 5).
Results
The rates of CNVs among the case and control groups are
presented in Table 1. For 13 out of the 15 CNVs, we found higher
rates in the case than in the control group. For six of these, the
difference was nominally significant in this new sample alone
(Table 1).
Of the loci where previous evidence was modest, the most
striking result was for AS/PWS duplications, where we found eight
in patients and none in controls (P=0.0055). When combined
with previous data (Table 2, for a more detailed version that
includes results from previous studies see online Table DS6), this
CNV is now a strongly supported schizophrenia risk variant.
Moreover, as this is an imprinted locus, we tested the parental
origin of our eight duplications, and all were shown to be
maternal in origin, similar to the original publication.6 Duplication
at 16p13.11, another previously weakly associated CNV, now also
shows strong evidence in the combined data (Table 2).
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The only instances in our study where CNVs were more
common in the control than in the case group concern duplications
at VIPR2 and deletions at distal 16p11.2. In neither case is the
excess of CNVs in the control group significant. In the case of
VIPR2, meta-analysis is no longer supportive, whereas the
evidence for association at distal 16p11.2 remains nominally
significant (Table 2 and Table DS6). Analysis of only individuals
of European descent gave essentially the same results. The distrib-
ution of CNVs in the different data-sets and ethnic groups is
presented in Table DS3.
In the present sample, which is not subject to the potential
bias of including the original studies that discovered the
associations, about 2.5% of the case group and 0.9% of the control
group carry one of the CNVs in Table 1, a highly significant excess
(P= 1.4610712). Only four individuals in the case group carry
two of these CNVs (online supplement, section 6).
In the analysis of all 15 loci in the combined data (Table 2), all
but one of the CNVs showed significant evidence of association.
For 11 of these, the significance surpasses the threshold for multiple
testing correction that we suggest in the Method (P54.161074).
For many of them the statistical significance is greatly improved
compared with the previous results, most strikingly for 15q11.2,
AS/PWS, 16p13.11, 16p11.2 and 22q11.2, where the P-values were
strengthened by several orders of magnitude.
Discussion
In an analysis of the largest single schizophrenia sample to date,
we establish more accurate estimates of risk from individual CNVs
in an independent sample, and estimate the total burden of
susceptibility conferred by this group of CNVs. The vast majority
110
Table 1 Findings from our data-set for previously implicated copy number variation (CNV) loci in schizophreniaa
Case group (n=6882) Control group (n=6316)
Locus Position in Mb CNVs, n Frequency, % CNVs, n Frequency, % OR (95% CI) P
1q21.1 del chr1:146,57-147,39 12 0.17 1 0.016 11.03 (1.43–84.86) 0.0027
1q21.1 dup chr1:146,57-147,39 8 0.12 5 0.079 1.47 (0.48–4.49) 0.35
NRXN1 del chr2:50,15-51,26 11 0.16 0 0.00 NA (1.25–:) 7.761074
3q29 del chr3:195,73-197,34 4 0.058 0 0.00 NA (0.44–:) 0.074
WBS dup chr7:72,74-74,14 3 0.044 1 0.016 2.75 (0.29–26.48) 0.35
VIPR2 dup chr7:158,82-158,94 1 0.015 6 0.095 0.15 (0.02–1.27) 0.99
15q11.2 del chr15:22,80-23,09 44 0.64 26 0.41 1.56 (0.96–2.53) 0.046
AS/PWS dup chr15:24,82-28,43 8 0.12 0 0.00 NA (0.90–:) 0.0055
15q13.3 del chr15:31,13-32,48 4 0.058 2 0.032 1.84 (0.34–10.03) 0.38
16p13.11 dup chr16:15,51-16,30 24 0.35 12 0.19 1.84 (0.92–3.68) 0.056
16p11.2 distal del chr16:28,82-29,05 0 0.00 2 0.032 NA (0–3.82) 1
16p11.2 dup chr16:29,64-30,20 27 0.39 0 0.00 NA (3.09–:) 2.361078
17p12 del chr17:14,16-15,43 4 0.058 3 0.047 1.22 (0.27–5.47) 0.55
17q12 del chr17:34,81-36,20 1 0.015 0 0.00 NA (0.11–:) 0.52
22q11.2 del chr22:19,02-20,26 20 0.29 0 0.00 NA (2.28–:) 2.261076
Totals 171 2.48 58 0.92 1.4610712
del, deletion; dup, duplications, NA, not applicable; WBS, Williams–Beuren syndrome; AS/PWS, Angelman/Prader–Willi syndrome.
a. Copy number variation positions are in UCSC Build 37. Significant results are in bold (using Fisher exact test, 1-tailed).
Table 2 Combined results of previous studies and the current data-seta
CNV frequency, % (n/N)
Locus P-value in previous studies Case group Control group OR (95% CI) P
1q21.1 del 1.361079 0.17 (33/19 056) 0.021 (17/81 821) 8.35 (4.65–14.99) 4.1610713
1q21.1 dup 2.061074 0.13 (21/16 247) 0.037 (24/64 046) 3.45 (1.92–6.20) 9.961075
NRXN del 7.961079 0.18 (33/18 762) 0.020 (10/51 161) 9.01 (4.44–18.29) 1.3610711
3q29 del 2.361078 0.082 (14/17 005) 0.0014 (1/69 965) 57.65 (7.58–438.44) 1.561079
WBS dup 5.561075 0.066 (14/21 269) 0.0058 (2/34 455) 11.35 (2.58–49.93) 6.961075
VIPR2 dup 0.006 0.11 (15/14 218) 0.069 (17/24 815) 1.54 (0.77–3.09) 0.27
15q11.2 del 2.261077 0.59 (116/19 547) 0.28 (227/81 802) 2.15 (1.71–2.68) 2.5610710
AS/PWS dup 0.014 0.083 (12/14 464) 0.0063 (3/47 686) 13.20 (3.72–46.77) 5.661076
15q13.3 del 2.1610711 0.14 (26/18 571) 0.019 (15/80 422) 7.52 (3.98–14.19) 4.0610710
16p13.11 dup 0.03 0.31 (37/12 029) 0.13 (93/69 289) 2.30 (1.57–3.36) 5.761075
16p11.2 distal del 0.0014 0.063 (13/20 732) 0.018 (5/27 045) 3.39 (1.21–9.52) 0.017
16p11.2 dup 3.2610714 0.35 (58/16 772) 0.030 (19/63 068) 11.52 (6.86–19.34) 2.9610724
17p12 del 0.0004 0.094 (12/12 773) 0.026 (17/65 402) 3.62 (1.73–7.57) 0.0012
17q12 del 0.004 0.036 (5/14 024) 0.0054 (4/74 447) 6.64 (1.78–24.72) 0.0072
22q11.2 del 1.0610730 0.29 (56/19 084) 0.00 (0/77 055) NA (28.27–:) 4.4610740
del, deletion; dup, duplications; NA, not applicable; WBS, Williams–Beuren syndrome; AS/PWS, Angelman/Prader–Willi syndrome.
a. For a more detailed version of this table that includes the CNV frequency, % (n/N) from previous studies see online Table DS6. P-values are based on Fisher exact test, 2-tailed.
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of patients in this study were recruited on the basis that they have
a diagnosis of treatment-resistant schizophrenia according to their
psychiatrist and were taking clozapine for that indication. The
availability of clinician diagnoses allowed us to exclude the limited
number of samples from individuals with diagnoses other than
schizophrenia. The convention for psychiatric samples has been
that patient inclusion is based on research diagnoses arrived at
following detailed interview and phenotyping procedures (as is
the case in the CardiffCOGS sample in this study). As genome
analysis has become more affordable than the establishment of a
formal research diagnosis, the latter has now become the limiting
step for exploiting the microarray technology. The CLOZUK
sampling method offers a pragmatic approach to recruit unusually
large numbers of patients with schizophrenia, and nearly doubles
the number of patients with schizophrenia analysed in the
previous literature. The use of such samples is supported by
evidence that with the use of operationalised criteria, clinician
diagnoses of schizophrenia have high specificity and positive
predictive values when validated against research-based
approaches.30,31 Furthermore, we have reported findings that
support the validity of the individuals in CLOZUK as a
schizophrenia sample with genetic data, by demonstrating that
of the most strongly associated schizophrenia alleles in the
Psychiatric Genetics Consortium Stage 1, 85% (66/78) showed
the same direction of effect in the CLOZUK sample, sign test
P= 1.7610710.21 In the present study, the findings of very similar
rates of susceptibility CNVs in the CLOZUK sample compared
with previous samples (Table DS6), recruited using conventional
methods, support the comparability of the two types of samples.
In order to reduce the potential bias of using different arrays,
we used only Illumina platforms and only analysed those probes
common to all arrays. We used the z-score method to both
validate each CNV and check whether any CNV in the regions
in Table 1 had been missed.
The current study provides support for most previously
implicated CNVs, as we found higher rates in the case group than
in the control group for 13 of the 15 loci. The support is
particularly strong for duplications at 16p11.2 (P= 2.361078)
and at the AS/PWS critical region (P= 0.0055) and for deletions
at 22q11.2 (P= 2.261076), 1q21.1 (P=0.0027), NRXN1
(P= 7.761074) and 15q11.2 (P=0.046). All eight duplications
at the AS/PWS region were of maternal origin (online supplement,
section 5), thus supporting the original report.6 Two loci:
deletions at 15q11.2 and duplications at 16p13.11, that were not
supported in two recent papers,5,10 also receive support in the
current study and the statistical significance of their overall
association with schizophrenia is strengthened by several orders
of magnitude (Table 2).
Four of the loci in Table 2 do not surpass a significance
threshold that corrects for the multiple testing of large recurrent
CNVs (P54.261074), or for individual genes (P52.561076)
(see Method): duplications at VIPR2, and deletions at distal
16p11.2, 17p12 and 17q12.
Burden of schizophrenia-associated CNVs
Overall, 2.5% of the case group v. 0.9% of the control group carry
one or more of these CNVs. This is highly significant in this
completely independent data-set (P= 1.4610712). They are
associated with a range of odds ratios and each locus clearly makes
a different contribution to the increase in risk (Table 2). They are
also known to increase risk for other disorders, such as epilepsy
(15q11.232 and 15q13.333), congenital heart disease (1q21.134 and
22q11.235), attention-deficit hyperactivity disorder (16p13.1136)
and obesity (distal 16p11.237), and all but two (at VIPR2 and
17p12) increase risk for developmental delay and autism spectrum
disorders.1 The overall contribution is modest but the effect size is
sufficiently large to suggest that if seen in a patient, it is very likely
to be relevant to the disorder, although not sufficient to account
for the disease.
Summary of the findings for the individual loci
1q21.1 deletions and duplications
Deletions at 1q21.1 were among the first implicated loci.8,38 Our
new data provide strong support for their role in schizophrenia
(P=0.0027), with a frequency in the case group identical to that
in previous reports (0.17%),14 confirming an approximately
eightfold excess of deletions among patients, with an extremely
strong statistical support of P = 4.1610713 in the combined
literature (Table 2). Duplications at this locus have only been
implicated in one study,10 but with the addition of our data
(although not significant on its own), the evidence for
duplications at this locus in schizophrenia is now stronger
(P=9.961075).
NRXN1 deletions
The gene NRXN1 encodes for a presynaptic cell adhesion protein,
which binds with postsynaptic proteins called neuroligins and
plays a vital role in the formation, maintenance and release of
neurotransmitters in synapses.39 Exonic deletions disrupting this
gene have been consistently implicated in schizophrenia9,10,13,40
and autism spectrum disorder.41 The current study confirms their
role, as we found 11 exonic deletions in the case group (0.16%)
and none in the control group, P= 7.761074. This brings the
overall significance in the combined literature to P=1.3610711
(easily surpassing our multiple testing correction threshold for
individual genes of P52.561076), with approximately a ninefold
excess in the case group (Table 2). The positions of exon-disrupting
CNVs at this locus in our new data-set are shown in the online
supplement, section 4.
3q29 deletions
The role of this CNV in schizophrenia was first reported by Mulle
et al,12 and confirmed by Levinson et al.10 The finding of four
individuals in the case group with deletions and none in the
control group just fails to reach significance in our independent
sample (P= 0.074) but can be regarded as supportive independent
confirmation. With an overall significance of P = 1.561079, it is
another locus where the evidence for a role in schizophrenia is
very strong. Only one such deletion has been found in nearly
70 000 controls, indicating it is highly penetrant (Table 2).
WBS duplications
The reciprocal duplication of the WBS region was first implicated
as increasing the risk for autism.42 The region was implicated in
schizophrenia after the finding of a de novo duplication26 and
reached statistical support in a large collaborative study.16 The
finding of three individuals in the case group and one in the
control group with this duplication in our study constitutes only
modest support, but the overall strength of the evidence remains
strong, at P=6.961075.
VIPR2 duplications
The evidence for duplications disrupting this gene comes from
two studies that used largely overlapping samples.10,17 The overall
evidence from the previous literature was modest: P=0.006.14 As
we found duplications in six people in the control group and only
one in the case group, the evidence in favour of this locus is
no longer significant in the combined literature (P= 0.27). The
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positions of CNVs at this locus in our new data-set are shown in
the online supplement (section 4). Most CNVs at this gene are
large and covered with a high number of probes on the arrays
(medians of 381 kb and 66 probes, details in online Table DS4),
therefore they should be called reliably on these arrays. We also
examined the region with all available probes for CNV calling
on the different arrays, and with the z-score method, and found
no additional CNVs that had been missed. The rate in our control
group is slightly higher than in previous studies (0.095% v.
0.059%, Table 1 and Table DS6), although this difference is not
significant (P=0.4).
15q11.2 deletions
This was one of the first CNVs implicated in schizophrenia.20,38
However, a recent report of a higher rate in controls than that
reported in the original paper5 and the lack of support in the
study by Levinson et al10 clearly indicated the need for replication.
Here we found independent significant evidence for association
(P= 0.046), that strengthens the evidence in the combined analysis
to P=2.5610710 (Table 2).
AS/PWS duplications
The modest prior evidence for the role of this duplication of the
AS/PWS critical region in schizophrenia comes from a single
publication with just four observations in patients.6 We found
another eight CNVs in our case group and none in the control
group (P=0.0055), thus substantially strengthening this finding.
Even more notably, by using DNA methylation-sensitive high-
resolution melting-curve analysis of the SNRPN locus,29 which
does not require DNA from the parents, we found that all eight
duplications are of maternal origin, as in the original study. These
findings further underline the importance of imprinted genes (those
genes subject to parent of origin specific epigenetic regulation) in the
aetiology of psychosis and other neurodevelopmental disorders.43
These duplications are among the most common genetic
susceptibility factors for autism spectrum disorder, where they
are found in nearly 1:500 cases.44
15q13.3 deletion
This is also among the first implicated CNVs in schizophrenia,8,38
and received further strong support in the study by Levinson
et al.10 It was found at a ~tenfold higher rate in patients with
schizophrenia, with a strong statistical support in the previous
literature,14 P=2.1610711. Although we found only a twofold
excess in our case group in our new sample, at 0.058% v. 0.032%,
P=0.38, its role as a susceptibility factor for schizophrenia remains
very strong in the combined literature (P=4.0610710). This locus
also increases the risk for epilepsy.33,45
16p13.11 duplication
The previous evidence for this CNV comes mostly from a single
study7 and the overall number of analysed patients with schizo-
phrenia so far, at 5147 individuals, is smaller than in our new
data-set. Two recent studies5,10 weakened the evidence for this
locus, and in the recent review by Malhotra & Sebat14 it had very
weak statistical support, P=0.03. Here we found 24 CNVs in the
case group and 12 in the control group, an excess that just fails to
reach significance, P= 0.056. Combined with the earlier data,
our study strengthens the statistical support for this locus in
schizophrenia to P= 5.761075. This CNV has also been
implicated in attention-deficit hyperactivity disorder.36
16p11.2 duplication
This is our strongest finding, with a P=2.361078 in the discovery
sample alone, and a combined evidence at P=2.9610724, with an
odds ratio of over 11. This duplication is also one of the strongest
autism spectrum disorder CNV risk factors.44
16p11.2 distal deletion
This CNV was suggested to confer susceptibility to schizophrenia
by Guha et al.18 We found no support for this locus in the present
study, with two deletions in the control group and none in the
case group. However, the lack of deletions among our case group
could be as a result of ascertainment bias. Obesity is found in at
least 50% of 16p11.2 distal deletion carriers.46 Clozapine produces
the most severe weight gain among all antipsychotics47 and the
most common cause for the reluctance of UK psychiatrists to
prescribe clozapine is the potential weight gain.48 It is therefore
possible that psychiatrists are less likely to give clozapine to
carriers of 16p11.2 distal deletion (as such patients are more likely
to be obese already), thus potentially reducing the frequency of
this CNV in the CLOZUK sample. The combined result from
the literature retains the statistical support for the role of this
locus (P= 0.017), but it clearly requires testing in further data-sets.
17p12 deletion
This deletion causes the neurological disorder hereditary neuropathy
with liability to pressure palsies and was implicated in schizo-
phrenia on the basis of only eight observations in the original case
group.20 Although the overall statistical evidence is still in favour
of it increasing the risk for schizophrenia (P=0.0012), the support
is not compelling, raising the need for further replication. It does
not increase the risk for either developmental delay or autism,1
unlike most other loci discussed here, and it is possible that the
original report was a false-positive finding.
17q12 deletion
Originally this locus had been known to cause renal cysts and
diabetes. It was identified as a susceptibility CNV for schizophrenia
with only four observations in the case group19 in a study that also
implicated its role in autism spectrum disorder. We found only
one deletion in a patient, a rate a quarter of that in the original
study.19 Although we found no deletions in the control group,
the overall P-value of all data is not sufficiently robust to
definitively conclude that this is a schizophrenia susceptibility
locus (P= 0.0072). Therefore, this locus also requires testing in
further schizophrenia data-sets.
22q11.2 deletion
This was the first CNV implicated in schizophrenia2,49 and has
received extensive replication over the years.10 It affects ~40 genes
and leads to a variety of physical anomalies.50 The latest review
found a rate of 0.30% in patients and 0% in controls.14 This rate
is practically identical to our new sample, where we found 20
carriers in the case group (0.29%) and none in the control group.
It remains the most significantly associated CNV in schizophrenia:
P= 4.4610740.
Implications
Out of 15 previously implicated CNV loci, 11 are now strongly
associated with schizophrenia from the combined results of the
previous literature and our new data. The evidence for the
remaining four loci should be regarded as still equivocal and
requiring further investigation. Our findings indicate that
approximately 2.5% of individuals with schizophrenia carry at
least one known pathogenic CNV. The odds ratios of these CNVs
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Copy number variations at 15 schizophrenia-associated loci
in relation to schizophrenia range between ~2 and 450 and
nearly all of them are also associated with a range of other
neurodevelopmental disorders, such as autism spectrum disorder
and intellectual deficit.1 Moreover, a number of the individual
pathogenic CNVs are associated with particular physical disease
phenotypes such as epilepsy (15q11.2 and 15q13.3), congenital
heart disease (1q21.1 and 22q11.2), microcephaly (1q21.1, 3q29
and 16p11.2) and obesity (16p11.2 distal).1,32–37,45,51 Given their
frequency, these findings therefore suggest that routine screening
for CNVs should be made available and that the results will have
immediate implications for genetic counselling, and given their
comorbidity with other medical disorders, for patient manage-
ment as well. The robust identification of 11 relatively high
penetrance risk alleles for schizophrenia also offers promise for
biological research aimed at developing animal and cellular
models for the identification of novel disease mechanisms and
drug targets.
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